Research programme: high molecular weight GPBP therapeutics- FibrostatinAlternative Names: FSM 26; FST 12; GPBP inhibitor; GPBP-Mab; T-12
Latest Information Update: 02 Nov 2016
At a glance
- Originator FibroStatin
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein serine threonine kinase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Diabetes mellitus; Idiopathic pulmonary fibrosis; Kidney disorders; Non-small cell lung cancer